Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Post by bbzzzzon Mar 06, 2019 1:08pm
167 Views
Post# 29450475

Paid to wait? Dividend? Worth a proxy battle? Respect for ..

Paid to wait? Dividend? Worth a proxy battle? Respect for .. shareholders ?

We all see that Mr. Goodman loves a good dividend. Gud receives dividends from many private equity pharma based deals as well as from Medison I pressume to keep the lights on but where is the respect for shareholders ?

 I wish to thank everyone for bringing up many points of interest and fact about Gud and the possible proxy battle that may develop. I wish to simply bring out the fact that management generates income via dividends but stops at the shareholder participating in this by having no ( love ) dividend. The cash hoard and the generated dividends do not allow us to say " at least we are being paid to wait ". A dividend would create an urgency for performance while shareholders allow for the management to develop a growth strategy. 
 With a " no respect for shareholders " policy as well as what is being displayed now with the new revelations of what is really happening or not happening in the boardroom i would suggest that a proxy battle just for the sake of a dividend alone should move ahead.
 
Again , there are many points that have been made here and I wish to thank everyone and encourage all to continue to post and comment as we all learn more about Gud. I simply wish to point out that a dividend is essential as we move forward with respect for all Shareholders !
 I hope to learn as we move through this situation and welcome all comments.
 tedz
Bullboard Posts